Daiichi Sankyo Gains Marketing Rights To Ajinomoto's Diabetes Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.